All articles by
Gustave Roussy and THERYQ: France welcomes the first FLASH radiotherapy machine to treat patients
Gustave Roussy and THERYQ announce a strategic and structuring partnership to roll out and assess FLASH technology for radiotherapy. French medical technology company THERYQ, specializing in particle accelerators and radiotherapy systems, has provided Gustave Roussy’s Department of Radiotherapy with the first FLASH clinical radiotherapy machine in France for treating superficial tumours.
Study Proves iTind Treatment for Enlarged Prostate Lasts More than Four Years
Olympus Corporation, a global medical technology company, announced publication of study data demonstrating that the minimally invasive iTind™ treatment provides long-lasting relief of more than four years for people suffering from the symptoms of an enlarged prostate, also known as BPH.
Korro Bio and Frequency Therapeutics Announce Merger Agreement
Combined company is expected to have cash balance of approximately $170m at close, which is expected to provide cash runway through several value-creating milestones and into 2026
Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases
Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases.
Co-Diagnostics, Inc. Awarded Funding for Co-Dx PCR Home Platform from NIH RADx® Tech Program
The Company intends to use the funds awarded by the National Institutes of Health for completion of its upper respiratory panel multiplex on Co-Dx PCR Home™ platform
Caristo Diagnostics Applauds FDA Approval of Colchicine as First Anti-Inflammatory Drug for Cardiovascular Disease
Colchicine’s Approval Heightens the Need for Technologies Detecting Inflammation Specifically Related to Coronary Arteries
Gilead partners with CHAI, Penta to enhance HIV treatment uptake in children
The two public-private partnerships are intended to accelerate the development of dispersible paediatric human immunodeficiency virus medicines
Caribou announces positive data from dose escalation of CB-010 ANTLER Phase 1 trial
According to the data set of all 16 patients treated in this phase, CB-010 was generally well tolerated and the rate of adverse events was similar to autologous or allogeneic anti-CD19 CAR-T cell therapies
European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Zolbetuximab
The MAA is based on results from the Phase 3 SPOTLIGHT and GLOW clinical trials
Aspirion Announces Acquisition of Continuum Health Solutions
The acquisition of Continuum further reinforces Aspirion’s market leadership in complex claims management specific to MVA and TPL services